Market Cap | 19.92M | P/E | - | EPS this Y | 85.50% | Ern Qtrly Grth | - |
Income | -37.64M | Forward P/E | - | EPS next Y | -11.50% | 50D Avg Chg | - |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -3.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -63.00% |
Recommedations | 1.50 | Quick Ratio | 0.14 | Shares Outstanding | 28.06M | 52W Low Chg | 86.00% |
Insider Own | 7.09% | ROA | -80.28% | Shares Float | 11.67M | Beta | 1.71 |
Inst Own | 57.67% | ROE | - | Shares Shorted/Prior | -/- | Price | 0.02 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 1,098,677 | Target Price | 22.50 |
Oper. Margin | - | Earnings Date | May 12 | Volume | 2,559,857 | Change | -4.21% |
Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.
Oppenheimer | Outperform | Apr 12, 24 |
Piper Sandler | Overweight | Mar 14, 24 |
Piper Sandler | Overweight | Feb 5, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
DHILLON PUNIT | Chief Executive Offi.. Chief Executive Officer | Aug 25 | Buy | 0.02 | 881,000 | 17,620 | 25,683,957 | 08/31/23 |